These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: No increase in prevalence of hepatitis B surface antigen mutant in a population of children and adolescents who were fully covered by universal infant immunization.
    Author: Hsu HY, Chang MH, Ni YH, Chiang CL, Chen HL, Wu JF, Chen PJ.
    Journal: J Infect Dis; 2010 Apr 15; 201(8):1192-200. PubMed ID: 20210630.
    Abstract:
    BACKGROUND: Mutants of the a determinant of hepatitis B surface antigen (HBsAg) can escape neutralization by vaccine-induced antibodies and prevail in an immunized population. METHODS: We evaluated the a mutants in a pediatric population surveyed in 2004 and compared these findings with the data of previous surveys. RESULTS: There were 38 children and 74 adolescents who were HBsAg positive, and serum hepatitis B virus (HBV) DNA was obtained and tested from 31 and 34 of them, respectively. The a mutants were found in 7 (22.6%) of 31 HBV DNA-positive children and in 7 (0.10%) of 7234 children, the entire population that was surveyed in 2004. After the beginning of universal immunization, the very low prevalence of mutants has remained unchanged for 20 years. More a mutants were found in immunized than in nonimmunized HBV DNA-positive children aged 1-4 years old (31% vs 4%, P = .016) but not in those children aged 5-12 years old. Approximately 68% of immunized, mutant-infected children had carrier mothers. More a mutants emerged in children immunized with plasma-derived vaccines than in those immunized with recombinant vaccines (14 of 5166 vs 3 of 4970, respectively; P = .04). HBV DNA levels were significantly lower in hepatitis B e antigen-positive sera containing the G145R mutant than were levels in sera containing wild-type virus. HBsAg-negative sera containing a mutants had very low HBV DNA levels. CONCLUSIONS: Less infectivity of G145R, recombinant vaccine use, and mutant loss with older age seem to decrease the a mutant prevalence in an immunized population over time.
    [Abstract] [Full Text] [Related] [New Search]